Bundled Valenz solutions for surgeries, imaging, specialty infusions, and catastrophic care now fully integrated into HealthJoy's Benefits Operating System to drive additional 50%+ savings
Read MoreDr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon
Read MoreCompany remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027
REMINDER: Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates (click here to register)
Read More
Integration with Proscia's Concentriq platform will facilitate pharma companies, diagnostic assay and platform providers, and CROs in operationalizing companion diagnostic programs
Read More
Introducing Magnesium L-Theanine Complex™ for relaxation and restorative sleep, and TreBiome™, a full-spectrum pre-, pro-, and postbiotic supporting total microbiome balance and both gut and vaginal health.
Read More
The additional capacity at the Austin, Texas, center responds to sustained demand for adolescent residential mental health care, with the new beds expected to be available in August 2026.
Read MoreAs announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications
Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID)
Read MoreNeonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy
Read MoreJaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for rare IF diseases, including MVID
Read MorePatent expands intellectual property protection in one of the world's largest cartilage repair markets
GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair
Read More
The collaboration will enable the development, validation, and application of advanced AI technologies to identify clinically meaningful patient subgroups, support biomarker-driven clinical trials, and create a platform for biopharma partnerships advancing innovation and personalized medicine.
Read More72% of dentists say they're "very confident" hygiene appointments meet best-practice standards; only 29% of hygienists agree, according to a new survey of dental professionals from Alta Voice
Read MoreEuropean Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production
GelrinC®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant
Read MoreArticle discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure
Associated with significant toxicities to patients, PS has a lethal natural history, and PS reduction can potentially extend and save lives
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint
New peer-reviewed data published in the scientific journal Cartilage uses the complete set of follow-up data from GelrinC's Phase II study, which establishes GelrinC as a leader in long-term durable cartilage repair, using objective, quantitative MOCART assessment to demonstrate morphologic outcomes that consistently outperform other treatment modalities
The data presented by Regentis show that two years after treatment, the repaired cartilage appears very close to normal healthy cartilage, highlighting the long-term durability of GelrinC and reinforcing its competitive superiority in the cartilage repair landscape
GelrinC is already approved in Europe and currently in a pivotal Phase III U.S. FDA study
Read More